Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results